Baxter’s Failed IVIG For Alzheimer’s May Work In Subpopulations
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Looking for signals in subgroup analyses, Baxter finds hint of efficacy in ApoE4 carriers and moderately impaired patients and promises not to walk away from immunoglobulin theory without following up.
You may also be interested in...
Stock Watch: CSL Takes Knocks Punching Above Its Weight
CSL’s evolution from plasma fractioneer to biotech has reached the extent of an approved gene therapy just as gene therapy commercialization faces challenges. Meanwhile, in the post-pandemic inflationary environment, CSL’s margins in its biggest blood products division are impacted by increased donor fees and higher labor costs.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.